• Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter
• FY 2026 revenue guidance of US$950 million to US$970 million reaffirmed
• Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) provided a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026). Q1 2026 highlights include: unaudited Group revenue of US$230 million, up 11% quarter-over-quarter; FY 2026 revenue guidance of US$950 million to US$970 million reaffirmed; Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. The company also reported progress in its therapeutics pipeline, including the successful completion of Part 1 of the ProstACT Global Phase 3 trial for its lead prostate cancer therapy candidate TLX591-Tx, and advancements in other programs such as TLX250-Tx, TLX101-Tx, TLX090-Tx, and TLX597-Tx. In the Precision Medicine business, Telix continues to expand the commercial footprint of its PSMA imaging portfolio, with Illuccix now launched in 21 countries globally.

Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million, reflecting revenue from product sales in jurisdictions with a marketing authorization and a full year of revenue contribution from RLS.